Alladapt Immunotherapeutics

Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens.

Alladapt Immunotherapeutics headquartered in United States, North America, operates in the Biotechnology sector. The company focuses on Biotechnology and has secured $2.7B in funding across 12 round(s). With a team of 11-50 employees, Alladapt Immunotherapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Debt Financing - Alladapt Immunotherapeutics, raised $50.0M. Discover more about their projects, partnerships, and impact on our platform.